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Implementing the Key Action Statements: An
Algorithm and Explanation for Process of Care for the
Evaluation, Diagnosis, Treatment, and Monitoring of
ADHD in Children and Adolescents
Practice guidelines provide a broad
outline of the requirements for high-
quality evidence-based care. In sup-
port of consistent and comprehensive
care for children and adolescents with
symptoms of attention and hyperactiv-
ity disorders within a typical, busy pe-
diatric practice, the AAP has developed
the following suggested process-of-
care algorithm (see Supplemental Fig
2) that provides discrete and manage-
able steps through which a primary
care clinician can fulﬁll the key action
statements offered in the guideline.
The algorithm is entirely consistent
with the practice guideline and is
based on the practical experience and
advice of clinicians experienced in the
diagnosis and management of ADHD in
children and adolescents. Because of
the detail provided, the process algo-
rithm does not have the same level of
evidence base as the key action state-
ments that are provided in the practice
guideline. The steps of the algorithm
are based primarily on consensus
among expert clinicians.
This algorithm and each of its constit-
uent steps is not intended to be com-
pleted in any single ofﬁce visit or any
speciﬁc number of visits; the experi-
ence of the clinician, the volume of the
practice, the longevity of the relation-
ship between the clinician and family,
the severity of the concerns, the avail-
ability of records and school input, the
family’s schedule, and the reimburse-
ment structure will all play a role in
determining the pace at which a family
and child/adolescent move through
the process of care.
Similarly, continued systematic moni-
toring (to include reconsideration of
the diagnosis if improvements in
symptoms are not apparent) is an on-
going process, to be addressed
throughout the child’s/adolescent’s
care within the practice, and in transi-
tion planning as the adolescent moves
into the adult care system.
The algorithm assumes that the pri-
mary care practice has adopted men-
tal health surveillance and screening
as described by the AAP Task Force on
Mental Health.1 In light of the preva-
lence of ADHD, the severity of the con-
sequences of untreated ADHD, and the
availability of effective treatments for
ADHD, the AAP recommends that every
child/adolescent identiﬁed with signs
or symptoms suggestive of ADHD be
evaluated for ADHD. It is important to
document all aspects of the diagnostic
and treatment procedures in patients’
records. Use of rating scales for the
diagnosis of ADHD, for assessment for
comorbid conditions, and as a method
for monitoring treatment and provid-
ing information provided to parents,
such as management plans, can help
facilitate a clinician’s accurate docu-
mentation of the process.
SIGNS AND SYMPTOMS THAT
SUGGEST ADHD
4- to 18- y-old patient identified with signs or symptoms suggesting ADHD. 
Symptoms can come from parents’ direct concerns or the mental health screen 
recommended by the TFOMH
See TFOMH Algorithms 
See action statement 1
Many parents bring their child/adoles-
cent to the primary care clinician with
speciﬁc concerns about the child’s/ad-
olescent’s ability to sustain attention,
curb activity level, and/or inhibit im-
pulsivity. In these cases, it is clear that
the clinician should initiate an evalua-
tion for ADHD. However, in many in-
stances, the chief concern might in-
clude behaviors and characteristics
associated with ADHD without mention
of the core ADHD symptoms. For exam-
ple, children/adolescents might have
difﬁculty remaining organized, plan-
ning activities, or inhibiting their initial
thoughts or actions, which are behav-
iors that fall under the umbrella of ex-
ecutive functions or cognitive control.
Problems with executive functions are
correlated with ADHD. Moreover, chil-
dren/adolescents might have difﬁculty
making or keeping friends, following
the rules of the classroom, or regulat-
ing their behavior. Problemswithin the
realm of social relationships are also
correlated with ADHD. In these cases,
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SUPPLEMENTAL APPENDIX FIGURE 2
ADHD process-of-care algorithm. TFOMH indicates Task Force on Mental Health; CYSHCN, child/youth with special health care needs.1
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initiating the diagnostic evaluation
might be appropriate.
Perform Diagnostic Evaluation for
ADHD and Evaluate or Screen for
Coexisting Disorders
Ideally, the primary care ofﬁce staff
can ask the assistance of the parent(s)
in obtaining information on the pur-
pose of a visit at the time of scheduling.
If possible, an extended visit is often
desirable for the evaluation of ADHD.
As a general approach to the initial
evaluation, data on the child’s/adoles-
cent’s symptoms and functioning (eg,
home or school questionnaires)
should be gathered from parents,
school personnel, and other sources,
preferably before the visit. This strat-
egy allows the primary care pediatri-
cian to focus on pertinent issues for
that child/adolescent and family at the
time of the visit. Parental consent to
authorize the release of school data to
pediatric providers is important to ob-
tain. The process might be facilitated if
the family is given the responsibility to
provide other informants with the
questionnaires or data-collection
forms to be used and to request other
records and reports.
To make a diagnosis of ADHD, the clini-
cian needs to establish that at least 6
or more core symptoms per dimen-
sion presented in Supplemental Table
2 are present in either or both of the
dimensions of inattention and/or
hyperactivity/impulsivity.
Diagnostic criteria for ADHD in school-
aged children and adolescents include
documentation of the following crite-
ria:
● At least 6 of the 9 behaviors de-
scribed in the inattentive domain
occur often and to a degree incon-
sistent with the child’s developmen-
tal age, and/or
● At least 6 of the 9 behaviors de-
scribed in the hyperactive/impul-
sive domain occur often and to a de-
gree inconsistent with the child’s
developmental age.
● Presence of some impairment in 2
or more major settings (eg, home
and school) for at least 6 months.
● Presence of some symptoms of
ADHD that caused impairment (ac-
cording to the history) before 7
years of age.
● Symptoms have persisted for at
least 6 months.
● Evidence of signiﬁcant clinical im-
pairment in social, academic, or oc-
cupational functioning because of
the behaviors.
● Symptoms are not attributable to
another physical, situational, or
mental health condition.
DSM-IV-TR2 criteria deﬁne 3 subtypes
of ADHD:
● ADHD primarily of the inattentive
type (ADHD/I, having the inappropri-
ately often occurrence of at least 6
of 9 inattention behaviors and 6
hyperactive-impulsive behaviors);
● ADHD primarily of the hyperactive-
impulsive type (ADHD/HI, having the
inappropriately often occurrence of
at least 6 of 9 hyperactive-impulsive
behaviors and 6 inattention be-
haviors); and
● ADHD combined type (ADHD/C, hav-
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SUPPLEMENTAL TABLE 2 Core Symptoms of ADHD (Adapted From the DSM-IV-TR)
Inattention Dimension Hyperactivity-Impulsivity Dimension
Hyperactivity Impulsivity
Careless mistakes Fidgety Blurts answers before questions are completed
Difﬁculty sustaining attention Unable to stay seated Difﬁculty awaiting turn
Seems not to listen Moves excessively (restless) Interrupts/intrudes on others
Fails to ﬁnish tasks Difﬁculty engaging in leisure activities quietly
Difﬁculty organizing “On the go”
Talks excessively
Avoids tasks that require sustained attention
Loses things
Easily distracted
Forgetful
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ing the inappropriately often occur-
rence of at least 6 of 9 behaviors in
both the inattention and
hyperactive-impulsive dimensions).
There is also evidence that the criteria
are appropriate for preschool-aged
children3 and adolescents.4 The use of
speciﬁc DSM-IV-TR criteria decreases
variation among clinicians in how the
diagnosis is made and will facilitate
communication among professionals
and patients.
DSM-IV-TR criteria require evidence of
impairing symptoms before 7 years of
age. In some cases, the symptoms of
ADHD might not be recognized by par-
ents or teachers until the child is older
than 7 years, when school tasks be-
comemore challenging. In children for
whom the problems are identiﬁed af-
ter 7 years of age, history can often
identify an earlier age of onset of some
of the symptoms. Delayed recognition
might be seen more often in the inat-
tentive subtype of ADHD.5
If symptoms arise suddenly, without
previous history, primary care clini-
cians should consider other condi-
tions including head trauma, physical
or sexual abuse, neurodegenerative
disorders, mood or anxiety disorders,
substance abuse, or a major psycho-
logical stress in the family or school.
The requirements that a child must
have signiﬁcant impairment in func-
tion and some impairment in at least 2
settings are the most challenging as-
pects of the DSM-IV-TR criteria for the
clinician to obtain accurate informa-
tion. The presence of functional im-
pairments is often the most troubling
issue for children, families, and teach-
ers and is a central requirement in
making the diagnosis of ADHD6 (also
see Behavior Management”).
As was determined in the previous
guideline, parent and teacher rating
scales that use DSM-IV-TR criteria for
ADHD are helpful in obtaining the infor-
mation required to make a diagnosis
on the basis of the DSM-IV-TR criteria.
Broad-band rating scales that assess
mental health functioning in general
do not provide reliable and valid indi-
cations of ADHD diagnoses but might
help in screening for co-occurring be-
havioral conditions.7
No current instruments routinely used
in primary care practice reliably as-
sess the nature or degree of functional
impairment in children with ADHD, al-
though parent-report instruments
might help. Some measures that are
available are limited, because they
mostly provide only a global rating (eg,
the Strengths and Difﬁculties Ques-
tionnaire [SDQ] Impact Scale8 and the
Children’s Global Assessment Scale
[CGAS]9) or have more limited valida-
tion (eg, the performance component
of the Vanderbilt Scales10,11). Review of
documents, such as report cards and
results of standardized testing, and ev-
idence of detention, suspensions, or
expulsions from school can also serve
as evidence of functional impairment.
With information obtained from the
parent and school, the clinician will
need to make a clinical judgment
about the effect of the core and asso-
ciated symptoms of ADHD on academic
achievement, classroom performance,
family and social relationships, inde-
pendent functioning and safety/acci-
dental injuries, self-perception, leisure
activities, and self-care (such as bath-
ing, toileting, dressing, and eating). Ad-
ditional guidance regarding functional
assessment is available through the
AAP ADHD toolkit and the Task Force on
Mental Health.15,16
In the absence of other concerns and
ﬁndings on medical history, family and
social history, and physical examina-
tion of the child, no further diagnostic
testingwill help to reach the diagnosis.
Compared with clinical interviews,
standardized psychological tests, such
as computerized tests of attention,
have not been found to reliably differ-
entiate between youth with and with-
out ADHD.14,15 Appropriate further as-
sessment is indicated if an underlying
etiology is suspected. Assessments
such as screening for high lead levels,
low iron or ferritin levels or abnormal
thyroid hormone levels or imaging
studies should be pursued only if other
historic or physical information sug-
gests their presence. Conditions such
as sleep disorders, such as apnea, ab-
sence seizures, hyperthyroidism, or
mood or anxiety disorders might pres-
ent with ADHD symptoms and might be
relieved when the primary condition is
treated.
Current criteria do not describe gen-
der or developmental differences, al-
though numerous studies have found
that the frequency of symptomatic be-
haviors varies signiﬁcantly across
gender and age groups (for a review,
see Barkley16). Compared with other
girls, girls with ADHD experience more
depression, anxiety, distress, poor
teacher relationships, stress, external
locus of control, and impaired aca-
demics. Compared with boys with
ADHD, girls with ADHD experience
more impairment in self-reported anx-
iety, distress, depression, and external
locus of control. Furthermore, the be-
havioral characteristics speciﬁed in
the DSM-IV-TR, despite efforts to stan-
dardize them, remain subjective, to a
great extent, and may be interpreted
differently by different observers. Cul-
tural norms and expectations of par-
ents or teachers may inﬂuence the
perspectives of various informants.
The rates of ADHD and its treatment
have been found to be different for
different racial/ethnic groups.17,18 The
clinician must remain sensitive to cul-
tural differences in the appropriate-
ness of behaviors and perceptions of
mental health conditions. Other fac-
tors, such as poverty and access to
care, likely contribute to the cultural
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differences. These complexities in the
diagnosis mean that clinicians who
use DSM-IV-TR criteria must apply
them in the context of sound clinical
judgment.
The DSM-IV-TR does include a category
of “ADHD not otherwise speciﬁed.” This
category is meant for children who
meet many but not the full criteria for
ADHD, such as children who meet all
the symptom and impairment criteria
but whose age of onset is later than 7
years or children who have clinically
signiﬁcant impairment but do not
meet all the symptom requirements.
Clinically signiﬁcant impairment is re-
quired in diagnosing a child with ADHD.
Children with inattentive or hyperac-
tive/impulsive symptoms but less than
signiﬁcant impairment are character-
ized as having “problems.”
FAMILY
A comprehensive diagnostic evalua-
tion typically begins with identifying
the family’s chief concerns. The clini-
cian also needs to have the family
members complete a validated ADHD
instrument. Family members should
be asked to provide a history of signs
and symptoms. This history includes
determining the onset, frequency, and
duration of problem behaviors, situa-
tions in which they increase or de-
crease, previous treatments and their
results, and the family’s understand-
ing of the issues. The family history
should include any medical syn-
dromes, developmental delays, cogni-
tive limitations, learning disorders, or
mental illness in family members, in-
cluding ADHD and mood, anxiety, and
bipolar disorders. In addition, parental
tobacco and substance use is relevant
to risk factors for ADHD.17 Family mem-
bers might not have been formally di-
agnosed with ADHD; asking about fam-
ily members’ school experience and
problems similar to those of the pa-
tient might suggest undiagnosed
cases of ADHD.
Updating the medical history can fo-
cus on factors associated with ADHD,
such as preterm delivery, neonatal
problems, congenital infections, and
head trauma. The psychosocial his-
tory should include environmental fac-
tors, such as family stress and prob-
lematic relationships that might
contribute to the child’s/adolescent’s
overall functioning.
It is important to obtain history of con-
ditions that might mimic ADHD symp-
toms or might co-occur with the condi-
tion. Co-occurring conditions are
discussed later in the process algo-
rithm. Several available question-
naires also provide a screen for coex-
isting conditions and a report of
function. It is important to obtain a
history that would suggest lead expo-
sure, absence seizures, or other men-
tal illnesses such as anxiety or mood
disorders and Tourette disorder. A full
review of systems might also reveal
other symptoms, such as sleep distur-
bances, that may assist in formulating
a differential diagnosis and/or may be
considered in the development of man-
agement plans. The patient should also
be screened for hearing and/or visual
problems.
Primary sleep disorders, such as ob-
structive sleep apnea syndrome and
restless-leg syndrome/periodic limb-
movement disorder, might present
with symptoms of inattention, hyper-
activity, and impulsivity or are fre-
quently associated with ADHD.18–21 All
children being evaluated for ADHD
should be systematically screened for
symptoms of (ie, frequent snoring, ob-
served breathing pauses; restless
sleep, urge to move their legs at night;
daytime sleepiness) and risk factors
for (ie, adenotonsillar hypertrophy,
asthma/allergies, obesity; family his-
tory of restless-leg syndrome/periodic
limb-movement disorder, iron deﬁ-
ciency) primary sleep disorders.22
Sleep-assessment measures that have
been shown to be useful in the pediat-
ric primary care practice setting in-
clude brief screening tools25 and
parent-report surveys.26,27 Overnight
polysomnography should be strongly
considered for children with symp-
toms suggestive of and/or risk factors
for obstructive sleep apnea syndrome
and restless-leg syndrome/periodic
limb-movement disorder.28
In addition, even in the absence of pri-
mary sleep disorders, modest reduc-
tions in sleep duration, such as those
associated with environmentally re-
lated insufﬁcient sleep, might be asso-
ciated with detectable deterioration in
vigilance and attention in childrenwith
ADHD and should be evaluated and ad-
dressed.29 Common clinical presenta-
tions of insomnia in children with
ADHD include bedtime resistance, de-
layed sleep onset, night wakings, and
early-morning awakening. Both a base-
line assessment (ie, before initiating
treatment) and ongoing periodic
screening for sleep problems should
be included in the management of all
children with ADHD. Sleep diaries are
useful adjuncts in quantifying sleep-
onset latency and night wakings and
assessing variability in sleep pat-
terns.30 The differential diagnosis of in-
somnia in childrenwith ADHD includes:
● ADHD medication (stimulant and
nonstimulant) effects:
● Direct effects on sleep architec-
ture (ie, prolonged sleep-onset la-
tency and decreased sleep dura-
tion, increased night wakings)31–
33; and
● Indirect effects such as inade-
quate control of ADHD symptoms
in the evening and medication
withdrawal or rebound
symptoms.23,34
● Sleep problems associated with co-
existing psychiatric conditions (ie,
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anxiety andmood disorders, disrup-
tive behavior disorders).34,35
● Circadian-based phase delay in
sleep-wake patterns, which have
been shown to occur in some chil-
dren with ADHD, which results in
both prolonged sleep onset and dif-
ﬁculty waking in the morning.36
● Inadequate sleep hygiene (ie, incon-
sistent bedtimes and wake times,
absence of a bedtime routine, elec-
tronics in the bedroom, caffeine
use).37
● Intrinsic deﬁcit associated with
ADHD. Numerous studies have found
that nonmedicated children with
ADHD and no comorbidmood or anx-
iety disorders have signiﬁcantly
greater bedtime resistance, more
sleep-onset difﬁculties, and more
frequent night awakenings when
compared with typically developing
control children.38 In addition, some
children with ADHD seem to have ev-
idence of increased daytime sleepi-
ness even in the absence of a pri-
mary sleep disorder.39,40
A sound assessment of functioning in
major areas can then be used to con-
struct an educational and behavioral
proﬁle including not only concerns but
also strengths or talents. The most
common areas of functioning affected
by ADHD include academic achieve-
ment; peer, parent, sibling, and adult
authority-ﬁgure relationships; partici-
pation in recreation such as sports;
and behavior and emotional regula-
tion, including risky behavior. One sys-
tematic approach to the assessment of
function can use the framework of the
International Classiﬁcation of Func-
tioning, Disability, and Health.6,41
Suggestions and recommendations
for scales such as the modiﬁed Patient
Health Questionnaire-9 Modiﬁed for
Adolescents (PHQ-A)42 and Screen for
Child Anxiety Related Emotional Disor-
ders (SCARED)43 have been developed
by the AAP Task Force on Mental
Health.13 The situation might be more
complicated when parents disagree,
particularly in divorce situations when
parents with shared custody perceive
the child’s problems and strengths dif-
ferently. Under such circumstances,
the clinician must use communication
skills to ﬁnd a consensus on the diag-
nosis and plan. Eliciting information
from extended family members might
help clarify some of the differences.
SCHOOL AND/OR OTHER
COMMUNITY INFORMANTS
Multiple informants are required for
clinicians to determine the nature
and severity of symptoms, impact of
the symptoms on function in 2 or
more settings, and whether the
child/adolescent meets DSM-IV-TR
criteria for the diagnosis of ADHD. In
most cases, the teacher provides
those reports. The reports of parents
and teachers are often sufﬁcient for
the ADHD diagnosis, but information
from the patient is essential for iden-
tifying the internalizing conditions of
mood and anxiety disorders. Rating
scales recommended by the Task
Force on Mental Health may be help-
ful. In some circumstances, it might
be desirable to solicit information
from additional sources. School re-
ports, for example, might be more
difﬁcult to obtain—or less compre-
hensive—in cases that involve
preschool-aged children and adoles-
cents. Other adults who are active in
the life of an adolescent, such as
coaches, pastors, or scout leaders,
can be asked to complete rating
scales to develop a full proﬁle of the
adolescent, although the accuracy of
their reporting has not been studied
Teachers might indicate their major
concerns by using questionnaires
or verbal input by telephone or
through direct conversation. An ap-
propriate school representative
should be asked to complete a vali-
dated ADHD instrument or behav-
ior scale based on DSM-IV-TR criteria
for ADHD and provide observations
that might suggest coexisting or al-
ternative conditions, including dis-
ruptive behavior disorders, depres-
sion and anxiety disorders, tics, or
learning disabilities. Report of
function, both strengths and weak-
nesses, might be gleaned by ques-
tionnaires or academic records
that can include report cards; stan-
dardized testing in reading, mathe-
matics, and written expression; vali-
dated functional assessment tools
mentioned previously44; and previ-
ous psychoeducational evaluations.
These records can help establish a
child’s/adolescent’s proﬁle of aca-
demic and behavioral performance
in school, the presence of a learning
disability, difﬁculty in following
school rules, the quality of peer in-
teractions, and the extent of school
absences.
If the records indicate that the child
is having difﬁculty learning aca-
demic skills, the physician should de-
termine if the child has been as-
sessed for a potential learning
problem by the school, because
there is a high comorbidity between
learning disabilities and ADHD. The
school assessment might use a
response-to-intervention model as
part of the diagnostic process in
which learning problems are evalu-
ated on the basis of the child’s re-
sponse to evidence-based academic
interventions, or a multidisciplinary
team evaluation might be conducted
by the school. If the child has an Indi-
vidualized Education Program, this
document should be reviewed by the
clinician.
If the child continues to struggle de-
spite the school’s interventions and
treatment for ADHD, further psychoe-
ducational or neuropsychological as-
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sessment is necessary. The clinician
might want to recommend that the
evaluations be performed by an inde-
pendent psychologist or neuropsy-
chologist. Despite the importance of
the psychological assessments, in-
surance coverage is quite variable,
and families should be encouraged
to investigate their coverage when
pursuing independent psychological
evaluations. Financing community-
based evaluations has been ad-
dressed in a previous AAP state-
ment.45 Children with intellectual or
other developmental disabilities
might also have ADHD, but the as-
sessment in these cases is more
complicated, because one must en-
sure that the academic expectations
are matched to the child’s academic
abilities and the level of ADHD symp-
toms exceeds what would be ex-
pected for a child’s developmental
level. Primary care physicians in-
volved in assessing ADHD in children
with intellectual disabilities will
need to collaborate closely with a
school psychologist or independent
psychologist.
In addition to the academic informa-
tion, information should be re-
quested that characterizes the
child’s/adolescent’s level of func-
tioning with regards to peer,
teacher, and other authority ﬁgure
relationships; ability to follow direc-
tions; organizational skills; history of
classroom disruption; and assign-
ment completion. Administrative
reports of disciplinary action, such
as suspensions and expulsions, and
descriptions of behavior at school
reﬂect social function and behav-
ioral regulation and suggest the pos-
sibility of coexisting conditions.
For adolescents who have multiple
teachers, it is desirable to obtain be-
havior and impairment ratings from at
least 2 teachers in academic subjects
(eg, math and English teachers or, for
children/adolescents with learning
disabilities, a teacher in the area of
strong function and a teacher in the
area of weak function). The ADHD tool-
kit13 providesmaterials relevant to this
school data collection.
Teacher and parent reports frequently
disagree,46 and there alsomight be dis-
agreement between parents. These ob-
servations might not be inaccurate,
because parents and teachers ob-
serve the children under different cir-
cumstances. When there is disagree-
ment, it is helpful to obtain more
information such as the circumstance
under which the individuals observed
the child, the demands on the child
during those observations, the observ-
ers’ understanding of the behaviors
and how to deal with them, and the ob-
servers’ understanding of ADHD and
how it is treated as well as the role
they play with the child. As noted pre-
viously, obtaining information from ad-
ditional sources, such as grandpar-
ents, coaches, or Sunday school
teachers, can be helpful. The clini-
cian’s decision about the diagnosis is a
clinical judgment made on the basis of
all the information that is available.
CHILD/ADOLESCENT
The clinician should conduct an age-
appropriate interview, including the
child’s/adolescent’s concern regarding
his or her own behavior, and regarding
family relationships, peers, andschool. It
is important to include a discussion of
his or her strengths, goals, and difﬁcul-
ties. Along with the interview, the use of
an appropriate validated self-report
instrument of ADHD and co-existing
conditions, primarily for adolescents,
canaid in theassessmentof riskof ADHD
and anxiety and mood disorders. It is
also important to ask about delusional
thinking and suicidal thoughts or ac-
tions. This evaluation should also pro-
vide a baseline of the child’s/adoles-
cent’s self-identiﬁed report of function
at home, in school, at work, and among
peers as well as validated functional as-
sessment tools.44 Whenever possible, the
individual child’s or youth’s own view of
what heor shewould like to see changed
should be considered primary targets
for intervention, because these goals
might at times differ widely from parent
or school concerns.
The clinician must keep in mind the
tendency of many children/adoles-
cents to underreport their ADHD and
other disruptive behavior symptoms.
However, the baseline impressions of
the child/adolescent can then be used
as the basis for shaping the patient’s
understanding of ADHD and coexisting
symptoms as well as monitoring func-
tion in social, behavioral, and aca-
demic domains. Active involvement of
the children/adolescents might be
useful to empower them to under-
stand and participate in their own di-
agnostic formulation and, later, to ob-
tain “buy in” to their treatment plan
and improve adherence to treatment.
Recommendations of the AAP Task
Force on Mental Health and the Guide-
lines for Adolescent Depression in Pri-
mary Care (GLAD-PC)47,48 include using
validated diagnostic rating scales for
adolescent mood and anxiety disor-
ders for clinicians whowish to use this
format. In addition, the CRAFFT (car, re-
lax, alone, forget, friends, trouble) is
an available screen for substance
abuse.49
Clinical observations of the patient
should be recorded and include his or
her level of attention, activity, and im-
pulsivity during the encounter. An im-
portant caveat is that the ﬁndings seen
in other settings, including core symp-
toms, are often not observed during
ofﬁce visits.50
Special attention should be paid to lan-
guage skills in preschool-aged and
young school-aged children, because
difﬁculties with language can be a
symptom of a language disorder and
Supplemental Appendix
PEDIATRICS Volume , Number , SI7
predictor of subsequent reading prob-
lems; such language disorders might
present as problems with attention
and impulsivity. Likewise, social inter-
actions should be noted during the ex-
amination, because they are another
possible area of deﬁciency.
The physical and neurologic exami-
nation must be comprehensive. A
physical and neurologic examination
should be conducted to determine if
further medical or developmental as-
sessments are indicated. Baseline
height, weight, blood pressure, and
pulse measurements should be taken.
Among the signs to note are hearing
and visual acuity and cardiovascular
status. Dysmorphic features should
also be noted, because ADHD might be
associated with genetic syndromes
(eg, fetal alcohol syndrome and fragile
X). The neurologic evaluation should
include developmental andmental sta-
tus observations including affect; com-
munication skills, including speech
and language; tics; and gross and ﬁne
motor coordination. Many children
with ADHD will have poor coordination,
which might be severe enough to war-
rant a diagnosis of developmental co-
ordination disorder. The ﬁndings can
affect how well the child can perform
in competitive sports and can also ad-
versely affect his or her writing skills.
Through history and examination of
the child’s ﬁne and gross motor skills,
the clinician can identify these deﬁcits
and address them in the management
plan.
DSM-IV
diagnosis of 
ADHD?
As a result of the diagnostic evalua-
tion, a primary care clinician should be
able to answer the following ques-
tions:
● How many inattentive and hyperac-
tive/impulsive behavior criteria for
ADHD does the child/adolescent
meet across the major settings of
his or her life?
● Have these criteria been present for
6 months or longer?
● Was the onset of these or similar
behaviors present before the age of
7 years?
● What functional impairments, if any,
are caused by these behaviors?
● Could any other condition be a bet-
ter explanation for the behaviors?
● Is there evidence of coexisting prob-
lems or disorders?
On the basis of this information, the
clinician should be able to arrive at a
preliminary diagnosis.
OTHER DISORDERS
If symptoms arise suddenly, with-
out any previous history, primary
care clinicians should consider
other conditions, including head
trauma, physical or sexual abuse,
neurodegenerative disorders,
mood and anxiety disorders, sub-
stance abuse, or a major psycho-
logical stress in the family or in
school, such as bullying.
Exit this guideline.
Evaluate or refer, as 
appropriate.
appropriate.
Idenfy the child as 
CYSHCN if 
Yes
Other 
condition?
If the evaluation identiﬁes or sug-
gests that another disorder is the
cause of the concerning signs and
symptoms, then it is appropriate to
exit this algorithm. The approach in
that case is dictated by the results of
the evaluation. If a referral is made,
the primary care clinician should
frame the referral questions clearly
and expect these referral questions
to be answered in a manner that will
ensure that a comanagement plan
that addresses the families’ and
child’s/adolescent’s ongoing needs
for education and general and spe-
cialty health care is established. Re-
sources from the AAP Task Force on
Mental Health might be helpful.
TYPICAL OR DEVELOPMENTAL
VARIATION:
Provide educaon 
addressing concern (eg, 
expectaons for aenon 
as a funcon of age)
Enhanced 
Surveillance
Apparently 
typical or 
developmental 
variation?
Yes
Evaluation might reveal that the
child’s/adolescent’s inattention, ac-
tivity level, and impulsivity are within
the normal range of development;
mildly or inconsistently elevated in
comparison to peers; or not associ-
ated with any functional impairment
in behavior, academics, social skills,
or other domains. It is important for
the clinician to probe further to de-
termine if the parental concerns re-
garding the child/adolescent are at-
tributable to other issues in the
family, such as parental tension or
drug abuse in another family mem-
ber; whether they are caused by
other issues in school, such as social
pressures or bullying; or whether
they are within the spectrum of typi-
cal development. Parent education
about contributions to their con-
cerns and to the spectrum of devel-
opmental variation might be helpful.
Education about the range of typical
development and strategies for im-
proving a child’s/adolescent’s be-
haviors when they are problematic
might be helpful. A schedule of en-
hanced surveillance absolves the
family of the need to reinitiate con-
tact if the situation deteriorates. If a
recommendation for continued rou-
tine systematic surveillance is made,
then assurance that ongoing con-
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cerns can be revisited in future pri-
mary care visits would be important.
INATTENTION, HYPERACTIVITY, AND/
OR IMPULSIVITY (PROBLEM LEVEL):
Children/adolescents whose symptoms
do not meet the criteria for diagnosis of
ADHDmight still encounter difﬁculties or
impairment in some settings, as de-
scribed in the DSM-PC Child and Adoles-
cent Version.51
Professional consensus is that medica-
tion is not an appropriate treatment for
children/adolescents with inattention,
hyperactivity, and/or impulsivity prob-
lems that do not meet the DSM-IV-TR cri-
teria for ADHD. Children/adolescents
with these problems and their families
might beneﬁt from education, including
identifying and eliminating triggers that
prompt inattention, hyperactivity, or im-
pulsivity; behavior-management options,
including a behavior-therapy or parent-
ing program; strategies for improving
schoolperformanceorbehavior; and the
recommendations provided in the inat-
tention and hyperactivity/impulsivity
cluster guidance in the Task Force on
Mental Health ADHD toolkit.13
ATTENTION-DEFICIT/HYPERACTIVITY
DISORDER:
If the child/adolescent is found to meet
the DSM-IV-TR criteria for ADHD, includ-
ing commensurate functional disabili-
ties, suchdiagnosis shouldbemade, and
progress through theprocess-of-careal-
gorithm continues as shown.
Provide Education to the Family and
Child/Adolescent
Education for the family and child/
adolescent about ADHD is an impor-
tant element in the care plan when
ADHD is diagnosed or inattention, hy-
peractivity, and/or impulsivity (prob-
lem level) is identiﬁed. Family educa-
tion continues throughout the
course of treatment. It includes an-
ticipatory guidance in such areas as
transitions (eg, from elementary to
middle and middle to high schools
and from high school to college or
employment) and working with
schools and developmental chal-
lenges that might be affected by
ADHD, including driving, gender, and
drugs.
Family education includes all mem-
bers of the family, including develop-
mentally age-appropriate information
for the affected child/adolescent and
any siblings. Topics include the disor-
der; the symptoms; the assessment
process; commonly coexisting disor-
ders; treatment choices and their ap-
plication, likely effects, and outcomes;
long-term implications; impact on
school performance; and social
participation.
A critical piece of the treatment plan
is to empower children/adolescents
to understand their condition and
the degree of impairment that it has
on their daily life, including strate-
gies for addressing symptoms and
impairments. At every stage, this ed-
ucation must continue in a manner
consistent with the child’s/adoles-
cent’s own level of understanding. In
addition, it is helpful for a child/ado-
lescent with ADHD to know the name
of any medication that he or she will
be using as well as common adverse
effects.
The issue of how the patient thinks of
himself or herself is another area to
address; it should be clariﬁed that
the condition does not mean that he
Inattention and/or 
hyperactivity/impulsivity 
problems 
not rising to DSM-IV Diagnosis
Provide educaon of family and child 
re: concerns (eg, triggers for inaenon 
or hyperacvity) and behavior 
management strategies or school
based strategies 
Enhanced 
Surveillance
Apparently 
typical or 
developmental 
variation?
No
Provide educaon to family and child 
re: concerns (eg, triggers for 
inaenon or hyperacvity) and 
behavior-management strategies or 
based strategies 
DSM-IV
diagnosis of 
ADHD?
Coexisting 
conditions?
No
Yes
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or she is less smart than other chil-
dren/adolescents. It can also be
helpful to identify and support areas
of strength and help the child/ado-
lescent with ADHD to learn how to
identify when he or she needs help
and how to procure it.
Education for parents should include
proactive strategies that can help
make the home environment more
facilitative for their child/adolescent
with ADHD. For example, making ad-
aptations and providing structure
that enables the child/adolescent to
best use his or her strengths and
compensate for deﬁcits can be help-
ful to parents. Such strategies in-
clude providing greater consistency
in the parents’ behavior toward their
child/adolescent with ADHD, forming
daily routines and schedules, and
displaying house rules in prominent
places as visual reminders. It may
help parents to communicate about
their child’s/adolescent’s behavior
and each parent’s response as well
as the parental division of labor. It is
also important to check on the par-
ents’ well-being, because parents of
children/adolescents with ADHD fre-
quently are under stress and might
not take into consideration their own
well-being or that of other family
members. These concerns are par-
ticularly relevant when a parent also
has ADHD or associated conditions.
Parents will likely beneﬁt if they learn
about optimal ways to partner with
schools such that teachers can be-
come part of the educational and inter-
vention teams. Parents will beneﬁt
from being informed about school ser-
vices that are available to address
their child’s/adolescent’s needs, in-
cluding the Individuals With Disabili-
ties Education Act (IDEA) and the Reha-
bilitation Act (504) services provided
by their state, and the eligibility re-
quirements for them. With a parent’s
permission, the clinician can provide
the school with information from the
evaluation that will help the school de-
termine eligibility for special educa-
tion services and develop appropriate
adaptations. Advocacy and support
groups such as CHADD (Children and
Adults With Attention-Deﬁcit/Hyperac-
tivity Disorder) can also provide infor-
mation and support to families.
The ADHD toolkit13 provides lists of ed-
ucational resources including Web-
based resources, organizations, and
books that might be useful to parents
and students.
COEXISTING CONDITIONS:
If other disorders are suspected or de-
tected during the diagnostic evalua-
tion, an assessment of the urgency of
these conditions and their impact on
the ADHD treatment plan needs to be
made.
Urgent conditions, such as suicidal
thoughts or acts or other behaviors
with the potential to severely injure
the child/adolescent or other peo-
ple, such as severe temper out-
bursts or child abuse, should be ad-
dressed immediately with services
capable of handling crisis
situations.
The evidence shows that coexisting
conditions, such as oppositionality and
anxiety, might improve with treatment
of ADHD.51 For example, children with
ADHD and coexisting anxiety disorders
might ﬁnd that ADHD medications de-
crease anxiety symptoms as well as
ADHD behaviors. In the cases of severe
learning disorders or oppositional de-
ﬁant disorder, a trial of treatment for
ADHD might indicate whether the ap-
parent coexisting condition can be
modulated with treatment of the ADHD.
Other patients might require addi-
tional therapeutic treatments, such as
cognitive behavioral therapy or a dif-
ferent or additional medication, to ad-
equately treat the ADHD and coexisting
condition.
Untreated substance use disorder
needs to be addressed ﬁrst before
fully addressing the patient’s ADHD
treatments.
If the primary care clinician requires
the advice of another subspecialist,
then the clinician should consider
carefully when to initiate treatment for
ADHD. In some cases, it might be advis-
able to delay the start of medication
until the role of each member of the
treatment team is established. For ex-
ample, with some coexisting psychiat-
ric disorders, such as severe anxiety,
depression, and bipolar disorder, a co-
managing developmental behavioral
pediatrician or psychiatrist might take
Assess impact on 
treatment plan
Further evaluation/
referral as needed
Coexisting disorders 
preclude primary care 
Follow-up and 
establish co-
management plan
See TFOMH 
Algorithms
Yes
Provide educaon to family and child 
re: concerns (eg, triggers for 
inaenon or hyperacvity) and 
behavior-management strategies or 
No
Yes
DSM-IV
diagnosis of 
ADHD?
Coexisting 
conditions?
Yes
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responsibility for treatment of both
the ADHD and the coexisting illness.
At other times, such as in the case of a
child or adolescent with coexisting
mild depression or obsessive-
compulsive disorder, a mental health
clinician, developmental-behavioral
pediatrician, neurodevelopmental dis-
ability clinician, or child neurologist
may treat the coexisting condition
while the primary care clinician over-
sees the treatment for ADHD, or the
consulting physician may advise the
primary care physician about the
treatment of the coexisting condition
to the extent that the primary care phy-
sician is comfortable treating both the
ADHD and coexisting problems.
ESTABLISH MANAGEMENT TEAM
Identify child as 
CYSHCN
Establish team 
including 
coordination plan
Collaborate with 
family, school, 
and child to 
identify target 
goals.
IDENTIFY AS A CHILD/YOUTH WITH
SPECIAL HEALTH CARE NEEDS:
Any child who meets the criteria for
ADHD should be considered a child/
youth with special health care needs.
The AAP encourages clinicians to de-
velop systems that ensure that the
medical home needs of all children/
youth with chronic illnesses are met.
These needs—and strategies for
meeting them—are discussed in fur-
ther detail elsewhere in this guideline
and in other AAP resources such as
The Building Your Medical Home Tool-
kit and Addressing Mental Health Con-
cerns in Primary Care: A Clinician’s
Toolkit.43,53
Management Issues
Questions that are important to con-
sider in developing a management
plan include the following:
● Does the family need further assis-
tance in understanding the core
symptoms of ADHD and their child’s/
adolescent’s target symptoms and
coexisting conditions?
● Does the family need support in
learning how to establish, measure,
and monitor target goals?
● Have the family’s goals been identi-
ﬁed and addressed in the care plan?
● Does the family have an understand-
ing of effective behavior-
management techniques for re-
sponding to tantrums, oppositional
behavior, or poor compliance to re-
quests and commands?
● Is help needed for normalizing peer
and family relationships?
● Does the child/adolescent need help
in academic areas? If so, has a for-
mal evaluation been performed and
reviewed to distinguish work pro-
duction problems secondary to
ADHD from coexisting learning or
language disabilities?
● Does the child/adolescent need help
in achieving independence in self-
help or schoolwork production?
● Does the child/adolescent or family
require help with optimizing, orga-
nizing, planning, or managing
schoolwork ﬂow?
● Does the family need help in recog-
nition, understanding, or manage-
ment of coexisting conditions?
● Is there a plan in place to systemat-
ically educate the child/adolescent
about ADHD and its treatment as
well as the child’s/adolescent’s own
strengths and weaknesses?
● Is there a plan in place to empower
the child/adolescent with the knowl-
edge and understanding that will in-
crease his or her adherence to
treatments, and has that begun as
early as possible and been ad-
dressed at the child’s/adolescent’s
developmental level?
● Does the family have a copy of a care
plan that summarizes ﬁndings and
treatment recommendations that
can be updated and used in school
settings and other professional set-
tings so that the history and treat-
ment plan does not need to be con-
stantly reinvented?
● Is the follow-up plan sufﬁcient to
provide comprehensive, coordi-
nated, family-centered, culturally
competent, ongoing care?
COLLABORATE WITH THE FAMILY,
SCHOOL, AND CHILD/ADOLESCENT TO
IDENTIFY TARGET GOALS:
Whereas an initial stimulant medica-
tion trial might focus on normalizing
core symptoms of ADHD, a longer-term
comprehensive plan should focus on
identifying and addressing individual-
ized and speciﬁc behavioral, academic,
and social target goals and treat-
ments. The clinician should assist par-
ents, teachers, other informants, and
the child/adolescent in developing tar-
get goals in the areas of function most
commonly affected by ADHD: academ-
ics; peer, parent, or sibling relation-
ships; and safety in the community.
Other goals might be identiﬁed by us-
ing the International Classiﬁcation of
Function (ICF) analysis conducted in
the diagnostic phase of the clinical
pathway.6
It is not necessary to develop goals in
every area all at once. Families might
be encouraged to identify up to 3 of the
most impairing areas on which they
will initially work; parents and the
child/adolescent can then add other
targets as indicated by their relative
importance. Such an exercisewill facil-
itate greater understanding of the ef-
fects of the disorder on each member
of the family and might lead to an im-
proved collaboration in the develop-
ment of a few speciﬁc and measurable
outcomes. It is helpful to incorporate
the child’s/adolescent’s strengths and
resilient factors in considering target
goals and in generating a treatment
plan. Goals for the school require input
from the teachers in terms of both
identiﬁcation and measurement.
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Establishing measurable goals in in-
terpersonal domains and behavior in
unstructured settings might be partic-
ularly important. Whenever possible, it
is important to make progress “count-
able.” For behaviors such as “fre-
quency of yelling” or frequency of
missing assignments, charts may be
suggested as strategies for recording
the event so that parents, teachers, the
child/adolescent, and clinicians can all
agree on howmuch progress has been
made. In this way, successes can be
built on in a systematic way. Such
strategies can help a family accurately
assess and see progress of behavior
changes. A daily single-page report
card can be used to identify and moni-
tor 4 or 5 behaviors that affect function
at school, and these reports can be
shared with the parents. Other strate-
gies and tools are available to clini-
cians in the AAP ADHD toolkit13 and to
parents in the book ADHD: What Every
Parent Needs to Know.52
As treatment proceeds, in addition to
using a DSM-IV-TR–based ADHD rating
scale to monitor core symptom
changes, formal and informal queries
can be made in the areas of function
most commonly affected by ADHD (eg,
academic achievement; peer, parent,
or sibling relationships; and safety in
the community). Progress can also be
monitored by determining progress on
the target goals. At every visit, it is
helpful to gradually empower chil-
dren/adolescents to become full part-
ners in their treatment plan by adoles-
cence. Information from the school,
including ADHD symptoms (rating
scale completed by the teacher),
grades, and any other formal testing
results, are also helpful at these visits.
ESTABLISH TEAM AND
COORDINATION PLAN:
It is best for the treatment team to in-
clude everyone involved in the care of
the child/adolescent: the child/adoles-
cent, parents, teachers, the primary
care clinician, therapists, subspecial-
ists, and other adults (such as coaches
or religious leaders) who will be ac-
tively engaged in supporting and mon-
itoring the treatment of ADHD. It is
helpful for the primary care clinician
or an assigned “care coordinator” to
ensure that each team member is
aware of his or her role and that both
routine and as-needed communication
strategies and expectations for re-
ports (frequency, scope) are clear. Col-
laboration with the school goes be-
yond the initial report of diagnosis and
is best facilitated by agreement on a
standardized, reliable system for ex-
changing communications.
TREATMENT:
Medication
This treatment option is restricted to
children/adolescents who meet the di-
agnostic criteria for ADHD.
Although it is a rare occurrence55
and more evidence is required to
identify whether it is an increased
risk, it is important to obtain a
careful history of cardiac symp-
toms; a cardiac family history, par-
ticularly of arrhythmias, sudden
death, and death at a young age
from cardiac conditions; and vital
signs, cardiac physical examina-
tion, and further evaluation on the
basis of clinical judgment.
Stimulant medications and several
nonstimulant medications are now
available, as outlined in Supplemental
Table 3. The presence of a tic disorder
might affect the decision about which
medication to initiate for ADHD ther-
apy. With the greater availability of
medications approved by the FDA for
children/adolescents with ADHD, it has
become increasingly unlikely that clini-
cians need to consider the off-label use
of othermedications. The choice of for-
mulation depends on factors such as
the efﬁcacy of each agent for a given
child/adolescent, the preferred length
of coverage time, whether a child can
swallow pills or capsules, and ex-
pense. The extended-release formula-
tions are generally more expensive
than the immediate-release formula-
tions but might be preferred by many
families and children/adolescents, be-
cause they provide the beneﬁts of con-
sistent and sustained coverage with
fewer administrations per day. Long-
acting formulations usually preclude
the need for school-based administra-
tion of ADHD medication. Better cover-
age with fewer administrations leads
to greater convenience for the family
and, therefore, might also lead to bet-
ter adherence to the medication man-
agement plan. Some patients, particu-
larly some adolescents, might require
more than 12 hours of coverage to en-
sure adequate focus and concentra-
tion during evening study time and
driving; in these cases, a short-acting
preparation might be used in addition
to a long-acting preparation.
The ease with which preparations can
be administered and the minimization
of adverse effects are important for
the quality-of-life concerns that chil-
dren, youth, and parents express
around the decision to usemedication.
Opon: Medicaon
(ADHD only and past medical or 
family history of cardiovascular 
disease considered)
 Iniate treatment
Titrate to maximum beneﬁt, 
minimum adverse eﬀects
Monitor target outcomes
Opon: Behavior management 
(developmental variaon, 
problem or ADHD)
Idenfy service or approach
Monitor target outcomes
Opon: Collaborate with 
school to enhance supports 
and services (developmental 
variaon, problem, or ADHD) 
Idenfy changes
Monitor target outcomes
See action statement 5
See action statement 6
BEGIN TREATMENT
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Other context issues that should also
be considered in deciding which med-
ication to recommend include the time
of day when the targeted symptoms
occur, when homework is usually
done, whether medication remains ac-
tive when teenagers are driving,
whether medication alters sleep initia-
tion, and risk status for drug use.
All approved stimulant medications
are methylphenidate or amphetamine
compounds, which have similar effects
and adverse effects. Given the exten-
sive evidence of efﬁcacy and safety,
they remain the ﬁrst choice of medica-
tion treatment. Thus, the decision re-
garding which compound a clinician
ﬁrst prescribes should bemade on the
basis of individual preferences of the
clinician and family. Some children/ad-
olescents will respond better to or dis-
play more adverse effects with 1 com-
pound group or the other. Because
these effects cannot be determined in
advance, if a trial with 1 group is un-
successful (poor efﬁcacy or adverse
effects), a trial on a medication from
the other group should be undertaken.
For cases in which there is concern
about possible abuse or diversion of
the medication or there is a strong
family preference against stimulant
medication, an FDA-approved non-
stimulant medication may be consid-
ered as the ﬁrst choice of medication.
The medications that use a microbead
technology can be opened and sprin-
kled on food for patients who have dif-
ﬁculty swallowing tablets or capsules.
Immediate-release methylphenidate,
which comes in liquid and chewable
forms, and a methylphenidate trans-
dermal patch are also available as al-
ternatives to tablets or capsules.
It is helpful to prepare families for the
initial medication (titration) process,
including what it will entail and how
long itmight take. The usual procedure
is to begin with a low dose of medica-
tion and titrate to the dose that pro-
vides maximum beneﬁt and minimal
adverse effects. Initially, core symp-
tom reduction ismore likely to indicate
medication effects; the effects of im-
SUPPLEMENTAL TABLE 3 FDA-Approved Medications: Dosing and Pharmacokinetics
Medication Brand Initial Titration Dose Frequency Time to
Initial Effect
Duration, h Maximum Dose Available Doses
Mixed amphetamine
salts
Adderalla 2.5–5.0 mg QD–BID 20–60 min 6 40 mg 5.0-, 7.5-, 10.0-, 12.5-, 15.0-,
20.0-, and 30.0-mg tablets
Adderall XRa 5 mg QD 20–60 min 10 40 mg 5-, 10-, 15-, 20-, 25-, and 30-mg
capsules
Dextroamphetamine Dexedrinea/
Dextrostat
2.5 mg BID–TID 20–60 min 4–6 40 mg 5- and 10-mg (Dextrostat only)
tablets
Dexedrine
Spansulea
5 mg QD–BID 60 min 6 40 mg 5-, 10-, and 15-mg capsules
Lisdexamfetamine Vyvanse 20 mg QD 60 min 10–12 70 mg 20-, 30-, 40-, 50-, 60-, and 70-
mg capsules
Methylphenidate Concerta 18 mg QD 20–60 min 12 54 mg (13 y); 72
mg (13 y)
18-, 27-, 36-, and 54-mg
capsules
Methyl ER 10 mg QD 20–60 min 8 60 mg 10- and 20-mg tablets
Methylin 5 mg BID–TID 20–60 min 3–5 60 mg 5-, 10-, and 20-mg tablets and
liquid and chewable forms
Daytrana 10 mgb Apply for 9 h 60 min 11–12 30 mg 10-, 15-, 20-, and 30-mg
patches
Ritalina 5 mg BID–TID 20–60 min 3–5 60 mg 5-, 10-, and 20-mg tablets
Ritalin LA 20 mg QD 20–60 min 6–8 60 mg 20-, 30-, and 40-mg capsules
Ritalin SRa 20 mg QD–BID 1–3 h 2–6 60 mg 20-mg capsules
Metadate CD 20 mg QD 20–60 min 6–8 60 mg 10-, 20-, 30-, 40-, 50-, and 60-
mg capsules
Dexmethylphenidate Focalina 2.5 mg BID 20–60 min 3–5 20 mg 2.5-, 5.0-, and 10.0-mg tablets
Focalin XR 5 mg QD 20–60 min 8–12 30 mg 5-, 10-, 15-, and 20-mg
capsules
Atomoxetine Strattera 0.5 mg/kg per d, then increase
to 1.2 mg/kg per d; 40 mg/d
for adults and children at
154 lb, up to 100 mg/d
QD–BID 1–2 wk At least 10–12 h 1.4 mg/kg 10-, 18-, 25-, 40-, 60-, 80-, and
100-mg capsules
Extended-release
guanfacine
Intuniv 1 mg/d QD 1–2 wk At least 10–12 h 4 mg/d 1-, 2-, 3-, and 4-mg tablets
Extended-release
clonidine
Kapvay 0.1 mg/d QD–BID 1–2 wk At least 10–12 h 0.4 mg/d 0.1- and 0.2-mg tablets
QD indicates daily; BID, twice daily; TID, three times daily.
a Available in a generic form.
b Dosages for the dermal patch are not equivalent to those of the oral preparations.
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provement in function require a more
extended time period. Stimulant medi-
cations can be effectively titrated on a
3- to 7-day basis. During the ﬁrstmonth
of treatment, medication dose may be
titrated with a weekly or biweekly tele-
phone call to the family. The increasing
doses can be provided either by pre-
scriptions that allow dose adjust-
ments upward or, for some of themed-
ications, by 1 prescription of tablets/
capsules of the same strength with
instructions to administer progres-
sively higher amounts by doubling or
tripling the initial dose. Another ap-
proach similar to that used in the MTA
study56 is for parents to be directed to
administer different doses of the same
preparation, each for 1 week at a time
(eg, Saturday through Friday). At the
end of each week, teacher and parent
feedback and/or DSM-IV-TR–based
ADHD rating scales can be completed
through a telephone interview, fax, or
secure electronic system. In addition
to the ADHD rating scale, parents and
teachers should be asked to review ad-
verse effects and target goals.
A face-to face follow-up visit is recom-
mended by the fourth week of medica-
tion, during which clinicians review
the responses to the varying doses and
monitor adverse effects, pulse, blood
pressure, and weight. To ensure that
progress in symptom control is being
maintained, clinicians should continue
to monitor levels of core symptoms
and improvement in speciﬁed target
goals. A general guide for visits to the
primary care clinician is for the face to
face visits to occur initially on a
monthly basis, until there is a consis-
tent optimal response, and then every
3 months in the ﬁrst year of treatment.
Subsequent visits will depend on the
response but should occur at least 2
times per year, until it is clear that tar-
get goals are progressing and stable,
and then periodically as determined by
the family and the clinician. Recent re-
sults from the MTA study indicate that
there are a number of children/adoles-
cents who, by 3 years after starting
medication, continue to improve even
if the medication has been discontin-
ued.57 The ﬁndings suggest that chil-
dren/adolescents who are stable in
their improvement of ADHD symptoms
may be given a trial off medication af-
ter several years to determine if med-
ication is still needed. This process is
best undertakenwith closemonitoring
of the child’s/adolescent’s core symp-
toms and function at home, in school,
and in the community.
Whenever possible, improvements in
core symptoms and target goals
should be monitored in an objective
way (eg, going from 60% to 20%miss-
ing assignments per week [see the
ADHD toolkit13]), and the core symp-
toms can be monitored by use of one
of the DSM-IV-TR–based ADHD rating
scales such as the Vanderbilt ADHD
follow-up scales. Clinicians are en-
couraged to educate parents that al-
though medication can be effective
in facilitating schoolwork produc-
tion, it has not been shown to be ef-
fective in addressing learning dis-
abilities. A child/adolescent who
continues to experience academic
underachievement after attaining
some control of ADHD behavioral
symptoms should be assessed for a
coexisting condition, including learn-
ing and language disabilities, other
mental health disorders, or other
psychosocial stressors. Noncompli-
ance with the treatment plan should
also be assessed.
If the maximum dose of a stimulant
preparation is reached and less-
than-satisfactory results have been
achieved or intolerable adverse ef-
fects occur before adequate efﬁcacy
with a medication from one of the
stimulant groups (methylphenidate
or amphetamine), a medication from
the other stimulant group should be
recommended with a similar titra-
tion plan. At least half of the chil-
dren/adolescents whose symptoms
fail to respond to 1 stimulant medi-
cation may have a positive response
to the alternative medication.56
Families concerned about the use of
stimulants or with concerns about
abuse or diversion may choose to
start with atomoxetine or extended-
release guanfacine or extended-
release clonidine. In addition, those
whose symptoms do not respond to
either stimulant group might still re-
spond to atomoxetine or extended-
release guanfacine or extended-
release clonidine. Extended release
guanfacine or extended release clo-
nidine also may be added as an ad-
junctive therapy in children who par-
tially respond to stimulant
medication.
There is a block-box warning on
atomoxetine of the possibility of
suicidal ideation when initiating
medication management. Early
symptoms of suicidal ideation
might include thinking about self-
harm and increasing agitation. If
there are any concerns about sui-
cidal ideation in children pre-
scribed atomoxetine, further evalu-
ation, reconsideration about the
use of atomoxetine, and more fre-
quent monitoring should be consid-
ered, and if necessary, referral to a
mental health clinician should be
made.
Atomoxetine is a selective
norepinephrine-reuptake inhibitor
and might result in maximum re-
sponse only after approximately 4 to 6
weeks. Extended-release guanfacine
and extended-release clonidine are
2A-adrenergic agonists and might re-
sult in maximum response in approxi-
mately 2 to 4 weeks. Parents may be
encouraged to complete weekly symp-
tom and adverse-effect monitoring, as
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described previously, as an objective
measure to monitor efﬁcacy. Because
symptom change is more gradual with
atomoxetine and 2A-adrenergic ago-
nists than with stimulant medications,
families who have had previous expe-
rience with stimulants should bemade
aware of this fact. In some patients, a
modest effect of atomoxetine might be
seen in 1 week. Atomoxetine might
cause gastrointestinal tract symptoms
and sedation early in treatment, so it is
recommended to prescribe half the
treatment dose (0.5 mg/kg) for the
ﬁrst week. Appetite suppression can
also occur. Both 2A agonists can
cause the adverse effect of somno-
lence. In addition, it is recommended
that the medications be tapered when
discontinued to prevent a possible re-
bound in blood pressure.
Special Circumstances: Preschool-
Aged Children
Clinicians should initiate ADHD treat-
ment of preschool-aged children
(4 –5 years of age) with behavior
therapy and should also assess for
other developmental problems, es-
pecially with language. If children do
not experience adequate symptom
and functional improvement with be-
havior therapy (most programs are
10–14 weeks long, but the clinician
should check with the therapists
about their usual length of interven-
tion), the clinician should ﬁrst evalu-
ate the adequacy and parental ac-
ceptance of the therapy. If the
symptoms and/or functioning have
not improved and the child is at sig-
niﬁcant behavioral or developmental
risk because of ADHD, medication
can be prescribed, as described pre-
viously. It must be noted that, cur-
rently, the FDA has only approved
dextroamphetamine for ADHD in chil-
dren in this age group, although
there is little evidence to support its
safety and efﬁcacy. There is, how-
ever, evidence that methylphenidate
is safe and efﬁcacious for children in
this age group.58 Evidence58 suggests
that the rate of metabolizing methyl-
phenidate is slower in children 4 and
5 years of age, so they should be
started at a lower dose that is in-
creased in smaller increments. In ad-
dition, the preschool-aged children
studied in the multisite study58 had
more severe dysfunction, which
should be considered in the decision
to try treatment with methylpheni-
date. The additional criteria for de-
ﬁning moderate-to-severe impair-
ment include symptoms present for
at least 9 months and clear impair-
ment in both the home and day care/
preschool settings that has not re-
sponded to an appropriate
behavioral intervention. Limited evi-
dence59 and no FDA approval for chil-
dren in this age group are available
for atomoxetine, and no evidence or
approval for extended-release guan-
facine or extended-release clonidine
are available.
Special Circumstances: Adolescents
Clinicians should assess adolescent
patients with ADHD for symptoms of
substance use or abuse before begin-
ning medication treatment. If sub-
stance abuse is revealed, they should
have the patient stop the use, and they
should provide treatment or refer for
treatment for substance abuse before
beginning treatment for ADHD. Clini-
cians are also encouraged to monitor
symptoms and prescription reﬁlls for
signs of misuse or diversion of ADHD
medication.
Special concern should be taken to
provide medication coverage for
ADHD symptom control while driving.
Longer-acting or late-afternoon/
short-acting medications might be
helpful in this regard. Counseling for
adolescents around medication is-
sues should include dealing with re-
sistance to treatment and empower-
ing children/adolescents to take
charge of and own their medication
management as much as possible.
Techniques of motivational inter-
viewing might be useful in improving
adherence.60
Special Circumstances: Families and
Children/Adolescents Who Decline
Medication
The decision about what is the most
acceptable treatment for their child/
adolescent rests with the family, and
the clinician must respect that deci-
sion. The clinician should, however, ad-
dress any misinformation or concerns
about medication shared by the family,
encourage all other dimensions of
treatment, and provide appropriate
monitoring.
Special Circumstances: Inattention or
Hyperactivity/Impulsivity (Problem
Level)
Medication is not appropriate for chil-
dren/adolescents whose symptoms do
not meet DSM-IV-TR criteria for diagno-
sis of ADHD.
Behavior Management
Evidence-based parent training typi-
cally begins with 7 to 12 weekly group
sessions with a trained therapist or
certiﬁed instructor. The focus is on
parent education about ADHD, the
child’s/adolescent’s behavior prob-
lems, and difﬁculties in family relation-
ships. A typical program aims to im-
prove the parents’/caregivers’
understanding of the child’s/adoles-
cent’s behavior and to teach them
skills to help the child/adolescent to
reduce the behavioral difﬁculties
posed by ADHD.
Programs offer speciﬁc techniques for
reinforcing adaptive and positive be-
haviors and decreasing or eliminating
inappropriate behaviors, both of
which alter the motivation of the child/
adolescent to control attention, activ-
ity, and impulsivity. These programs
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emphasize establishing positive inter-
actions between parents and children;
learning how to shape children’s be-
haviors through combinations of
praising and ignoring; how to give suc-
cessful commands; how to reinforce
positive behaviors; how to extinguish
inappropriate behaviors through ig-
noring; how to identify which behav-
iors are handled most appropriately
through punishment; and determining
how to carry punishments out in a re-
sponsible way. These programs all em-
phasize teaching self-control and
building positive family relationships.
If parents strongly disagree about be-
havior management or have conten-
tious relationships, parenting pro-
grams will likely be unsuccessful.
Other strategies, such as changing the
physical environment to reduce stim-
uli to overactivity, are also effective by
changing the stimuli that trigger prob-
lem behaviors. Depending on the se-
verity of the child’s/adolescent’s be-
haviors and the capabilities of the
parents, group or individual training
programs will be required. Programs
typically include support for mainte-
nance and relapse prevention.
Behavior therapy should be differenti-
ated from psychological interventions
directed to the child/adolescent and
designed to change the child’s/adoles-
cent’s emotional status (eg, play ther-
apy) or thought patterns (eg, interper-
sonal talk therapy). These
psychological interventions do not
have a demonstrated efﬁcacy for the
ADHD core symptoms, and gains
achieved in the treatment setting usu-
ally do not transfer into the classroom
or home. By contrast, parent training
in behavior therapy and classroom be-
havior interventions have successfully
changed the behavior of children/ado-
lescents with ADHD.61 Behavior therapy
is also applicable for children/adoles-
cents who have problems in the do-
mains of inattention or hypersensitivi-
ty/impulsivity but do notmeet the DSM-
IV-TR criteria and for those children/
adolescents with a developmental
variation.
Unless primary care clinicians are
speciﬁcally trained, have trained staff
or a colocated therapist, or dedicate
many visits to providing the ongoing
treatment, they might not be effective
in providing behavior therapy.62 Clini-
cians might also have difﬁculties de-
termining the skills of behavior thera-
pists listed in the behavioral health
insurance plan. This determination is
important, because many therapists
focus on a play or interpersonal-talk
therapy that has not been shown to be
effective in treating the core symp-
toms of ADHD. Telephone inquiries of
therapists, agencies, and mental
health clinicians regarding their ap-
proach to behavior therapy might al-
low clinicians to develop a resource
list for parents. Clinicians might also
request references from other par-
ents of children/adolescents with
ADHD, professional organizations
(eg, Association for Behavior and
Cognitive Therapies), and ADHD advo-
cacy organizations (eg, CHADD). Par-
ents who have read authoritatively
written books about behavior thera-
py/behavior parent training might be
in a better position to know what
they are looking for in a therapist
and ask the salient questions when
seeking appropriate therapists.
Some of these resources are avail-
able in the ADHD toolkit13 and the
book ADHD: What Every Parent Needs
to Know.54
Classroom behavior management also
focuses on shaping the child’s/adoles-
cent’s behaviors and may be inte-
grated into classroom routines for all
students or targeted for a selected
child/adolescent in the classroom.
Classroom management often begins
with increasing the structure of activi-
ties. Token economy refers to using
points or tokens that are given for pos-
itive behaviors, and response cost re-
fers to points or tokens subtracted for
inappropriate behaviors. The tokens
or points can then be cashed in after a
deﬁned period for rewards or privi-
leges. Systematic rewards (eg, use of a
token economy) are included to in-
crease appropriate behavior and elim-
inate inappropriate behavior. A peri-
odic (often daily) behavior report card
can record the child’s/adolescent’s
progress or performance with regard
to goals and communicate the child’s/
adolescent’s progress to the parents,
who then provide reinforcers or con-
sequences based on that day’s perfor-
mance. Such programs are also useful
for the purpose of monitoring medica-
tion effects.
COLLABORATE WITH THE SCHOOL TO
ENHANCE SUPPORTS AND SERVICES
Many teachers and schools have effec-
tive strategies for supporting and
serving children/adolescents with
ADHD. Schools can implement
behavior-management programs that
directly target ADHD symptoms as well
as interventions to enhance academic
and social functioning. Schools may
also use strategies (eg, daily behavior
report cards) to enhance communica-
tion with families. All schools should
have specialists (eg, school psycholo-
gists, counselors, special educators)
who observe the child/adolescent,
identify triggers and reinforcers, and
support teachers in changing the cir-
cumstances of the classroom and
making accommodations to address
ADHD symptoms, such as written-
output bypass strategies, untimed
testing, testing in less distracting envi-
ronments, preferential seating, and
routine reminders.
Clinicians should be aware of the eligi-
bility criteria for the 504 Rehabilitation
Act and the IndividualsWith Disabilities
Education Act supports in their state
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and local school district(s)63 and
should understand the process for re-
ferral as well as the individuals with
whom the physician or parent should
make contact. This information can be
provided to parents to support their
efforts to request classroom adapta-
tions for their child/adolescent with
ADHD, including the use of empirically
supported academic interventions to
address achievement difﬁculties asso-
ciated with ADHD symptoms.
Do 
symptoms 
improve?
In providing a medical home, primary
care clinicians should regularly moni-
tor all aspects of ADHD treatment, to
include:
● systematic reassessment of core
symptoms and function;
● regular reassessment of target
goals;
● assurance that the family is satis-
ﬁed with the care they are receiv-
ing from other clinicians and thera-
pists, if applicable;
● provision of anticipatory guid-
ance, further child/adolescent
and family education, and transi-
tion planning as needed and
appropriate;
● assurance that care coordination
is occurring and meeting the needs
of the child/adolescent and family;
● conﬁrmation of adherence to any
prescribed medication regimen,
with adjustments made as needed;
● heart rate, blood pressure, height,
and weight monitoring; and
● continuing to form a therapeutic re-
lationship with the child/adolescent
and empower families and chil-
dren/adolescents to be strong, in-
formed advocates.
Some treatment monitoring can occur
during general health care visits if the
clinician inquires about progress to-
ward target goals, adherence to medi-
cation and behavior therapy, con-
cerns, or changes.
Monitoring of children/adolescents
with inattention or hyperactivity/im-
pulsivity problems can help to ensure
prompt treatment, should their symp-
toms worsen to the extent that a diag-
nosis of ADHD is warranted.
Reevaluate to confirm diagnosis 
and/or provide education to improve 
adherence.
Reconsider treatment plan including 
changing of the medication or dose, 
adding a medication approved for 
adjuvant therapy, and/or 
changing behavioral therapy.
No
ADHD treatment failuremight be a sign
of incorrect or incomplete diagnosis.
Clinicians are advised to repeat the full
diagnostic evaluation and pay in-
creased attention to the possibility of
coexisting conditions that mimic or
are associated with ADHD, such as
sleep disorders, Asperger syndrome,
or epilepsy (eg, absence epilepsy or
partial seizures). A coexisting learning
disordermight also cause an apparent
treatment failure. In the case of a
child/adolescent previously diagnosed
with problem-level inattention or hy-
peractivity, repeating the diagnostic
evaluation might result in a diagnosis
of ADHD, which would allow for in-
creased school supports and the inclu-
sion of medication in the treatment
plan.
Treatment failure could also signal
poor adherence to the treatment plan.
Increased monitoring and education,
especially by including the patient
early in his or her treatment, might in-
crease treatment adherence. It is help-
ful to try to identify the issues that re-
strict adherence.
Yes
Follow-up for 
chronic care 
management at 
least 2x/year for 
ADHD issues
In the early stages of treatment, after a
successful titration period, the fre-
quency of follow-up visits will depend
on adherence, coexisting conditions,
and persistence of symptoms. As
noted previously, a general guide for
visits to the primary care clinician is
for these visits to occur initially on a
monthly basis, then every 3 months in
the ﬁrst year of treatment. More fre-
quent visits might be necessary if co-
morbid conditions are present. Visits
should then be held at least twice each
year with additional telephone moni-
toring at the time of medication-reﬁll
requests. Ongoing communication
with the school regarding medication
and services is also needed.
It should be noted that at this point,
there is little evidence to establish the
optimal, yet practical, follow-up regi-
men. It is likely that the regimen will
need to be tailored to the individual
child/adolescent and family needs on
the basis of clinical judgment.
PREPARING THE PRACTICE
Speciﬁc ofﬁce practice procedures
that facilitate the optimal and efﬁcient
diagnosis and treatment process are
critical for successful management of
children/adolescents with ADHD. More
detail can also be found in the report of
the AAP Task Force on Mental Health.1
The ofﬁce process can include:
● developing a packet of ADHD ques-
tionnaires and rating scales for par-
ents and teachers to complete be-
fore a scheduled visit;
● allotting adequate time for ADHD-
related visits;
● determining appropriate billing,
documentation, and monitoring of
insurance payments to ensure that
they adequately cover the services
rendered;
● implementing methods to track and
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follow-up patients (refer to medical
home procedures for more detail);
● asking questions during all clinical
encounters and placing brochures
and posters in the ofﬁce to alert par-
ents and children/adolescents that
behavior and school problems and
ADHD are appropriate issues to dis-
cuss with the clinician;
● developing an ofﬁce system for
monitoring and titrating medication
(a follow-up system should include
the clinician’s assessment of family
organization, telephone access, and
parent-teacher communication ef-
fectiveness); and
● collaborating with schools and
other involved community providers
and resources that can enhance the
process for ADHD diagnosis and
management, which can be
achieved on a case-by-case basis
through coordination of the diagno-
sis and treatment plan among
school staff, the clinician, parents,
and other involved professionals
(note that this less-systematic ap-
proach carries signiﬁcant chal-
lenges, including ensuring consis-
tent care for all children/
adolescents with ADHD).
A community-level system that reﬂects
consensus among district school staff
and local primary care clinicians for
key elements of diagnosis, interven-
tions, and ongoing communication can
help to ensure consistent, well-
coordinated, and cost-effective care. A
community-based systemwith schools
relieves the individual primary care
clinician from negotiating with each
school about care and communication
regarding each patient. Ofﬁces that
have incorporated medical home prin-
ciples are ideal for establishing this
kind of community-level system. The
key elements for a community-based
collaborative system include consen-
sus on:
● a clear and organized process by
which an evaluation can be initiated
when concerns are identiﬁed by ei-
ther parents or school personnel;
● a packet of information completed
by parents and a teacher about
each child/adolescent referred to
the primary care clinician;
● a contact person at the practice to
receive information from parents
and teachers at the time of evalua-
tion and during follow-up;
● an assessment process to investi-
gate coexisting conditions;
● a directory of evidence-based inter-
ventions available in the
community;
● an ongoing process for follow-up
visits, telephone calls, teacher re-
ports, and medication reﬁlls;
● availability of forms for collecting
and exchanging information; and
● a plan for keeping school staff and
primary care clinicians up-to-date
on the process.
The clinician might face challenges to
developing such a collaborative pro-
cess. As examples, the primary care
provider might be caring for children/
adolescents from more than 1 school
system; a school systemmight be quite
large and not easily accessed; schools
might have limited staff and resources
to complete assessments; or it might
be difﬁcult for the physician and
teacher or other school personnel to
communicate by telephone because
their schedules differ. There are work-
able strategies for addressing each of
these challenges.
In the case of multiple or large school
systems in a community, the primary
care clinician might want to begin with
1 school psychologist or principal, or
several practices can initiate contact
collectively with a community school
system. Agreement among the clini-
cians on the components of a good
evaluation process facilitates cooper-
ation and communication with the
school toward common goals. For ex-
ample, agreement on the behavior rat-
ing scales used can facilitate comple-
tion by school personnel. Standard
communication forms that monitor
progress and speciﬁc interventions
can be faxed between the school and
the pediatric ofﬁce to share
information.
Collaborative systems also extend to
other providers who may comanage
care with the primary care clinician.
Providers may include a mental health
professional who sees the child/ado-
lescent for psychosocial interventions
or a specialist who addresses difﬁcult
cases, such as a developmental-
behavioral pediatrician, child psychia-
trist, child neurologist, neurodevelop-
mental disability physician, or
psychologist. Agreed-on processes for
routine communication can also be
used in these relationships. The AAP
Task Force onMental Health provides a
full discussion of collaborative rela-
tionships with mental health profes-
sionals, including colocation and inte-
grated models, in its Chapter Action
Kit64 and Pedialink Module.
It is important to note that good care
frequently requires activities that cur-
rently are not reimbursed. These activ-
ities include contacts with teachers
and mental health consultants and
non–face-to-face contact with parents
and patients. It would be helpful for cli-
nicians to document the nonreim-
bursed efforts and for the national
AAP, state chapters, and clinicians to
continue to try tomake third-party pay-
ers understand the need for these ef-
forts and provide compensation for
this appropriate care.
COMPLEMENTARY AND UNPROVEN
THERAPIES
Families of children/adolescents with
ADHD increasingly ask about comple-
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mentary and alternative therapies for
ADHD. Such therapies might include
large doses of vitamins, essential fatty
acids, and other dietary alterations;
chelation; and electroencephalo-
graphic (EEG) biofeedback.65 To date,
there is insufﬁcient evidence to deter-
mine whether these therapies lead to
changes in core symptoms of ADHD or
function, and for many of them, there
is limited information about their
safety. For these reasons, these thera-
pies cannot be recommended. Some
therapies, chelation, and megavita-
mins have been proven to cause some
adverse effects and are
contraindicated.
Physicians can play a constructive role
in helping families make thoughtful
treatment choices by reviewing the
stated goals or effects claimed for a
given treatment; the state of evidence
to support or discourage use of the
treatment; and known or potential ad-
verse effects. Physicians should en-
courage families that wish to pursue
these treatments to try 1 intervention
at a time, choose target goals they will
use, monitor core symptoms to mea-
sure efﬁcacy, and choose a time frame
in which they anticipate the changes to
occur. Families should also be strongly
encouraged to continue to use the
more evidence-based interventions at
the same time that they are exploring
complementary and alternative
treatments.
Clinicians should respect families’ in-
terests and preferences while they ad-
dress and answer questions about
complementary and unproven thera-
pies to preserve and enhance the clini-
cian/family relationship. In addition,
primary care clinicians should know
about additional therapies that fami-
lies might be administering to ade-
quately monitor for drug interactions.
Parents and children/adolescents who
do not feel that their choices in health
care are respected by their primary
care clinician might be less likely to
communicate about complementary
or alternative therapies.
Further information about comple-
mentary and other therapies pro-
moted for the treatment of ADHD can
be found in a chapter on this topic in
Developmental-Behavioral Pediatrics:
Evidence and Practice65 or in an article
in the Journal of Developmental and
Behavioral Pediatrics.52
CONCLUSION
ADHD is the most common neurobio-
logical disorder of children/adoles-
cents; untreated, ADHD can have far-
reaching and serious consequences
on their health and well-being. Fortu-
nately, effective treatments are avail-
able, as are methods for assessing
and diagnosing children/adolescents
with ADHD. The AAP is committed to
supporting primary care physicians in
providing quality care to children/ado-
lescents with ADHD and their families.
The algorithm presented here repre-
sents a portion of that commitment. It
is an effort to assist primary care cli-
nicians in delivering care that meets
the quality standards of the practice
guideline. Additional support and guid-
ance can be obtained through the
ADHD toolkit12 and the work and publi-
cations of the AAP Task Force on Men-
tal Health.13
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